AOD-9604
Also known as: Advanced Obesity Drug 9604, hGH fragment 177-191 analog
Quick summary
AOD-9604 is a modified fragment taken from the C-terminal end of human growth hormone. Research focus: lipolysis and fat oxidation in rodent models, beta-3 adrenergic receptor expression and energy expenditure measurement. This page leads with SRP's low-and-slow starting dose.
Overview
AOD-9604 is a modified fragment taken from the C-terminal end of human growth hormone. Researchers created it to isolate the fat-metabolism signaling of GH from its growth-promoting effects. Most published work comes from Monash University mouse studies of lipid handling and energy balance.
Looking for research material? Simple Research Peptides lists AOD-9604 (10 mg Vial) for laboratory research use.
Mechanism
A modified fragment from the C-terminal end of growth hormone (residues 177-191). It is studied for its fat-burning effects without the growth-promoting or blood-sugar effects of full-length growth hormone.
Research areas
- lipolysis and fat oxidation in rodent models
- beta-3 adrenergic receptor expression
- energy expenditure measurement
Storage & reconstitution
Supplied as a lyophilized powder; keep sealed, dry and away from light, ideally frozen or refrigerated for long-term holding. Laboratories typically reconstitute with bacteriostatic or sterile water, swirling gently rather than shaking, then hold the solution refrigerated (2–8 °C) and use it within the window set by their own stability protocol.
Recommended starting dose (low and slow)
| Starting dose | Example starts at 300 mcg once daily for the first 4 weeks. give ranges whose low end is 250-300 mcg. |
|---|---|
| Frequency | Reported schedules: daily, often fasted; 250–500mcg daily fasted; Daily; Daily. |
| Reconstitution | Examples: 5 mg vial + 2 mL bacteriostatic water = 2.5 mg/mL; 5mg vial + 3mL diluent (as listed). Different water volumes can be used; that only changes the draw volume, not the amount of peptide. storage note: Reconstituted: refrigerate, used within 4 weeks. |
Studied higher doses
Studies have used doses up to the amounts below. Higher doses can be dangerous. Whether a person can reach them safely depends on height, weight, activity level, training and pre-existing conditions. We recommend following the lower starting dose above, and contacting SRP with any questions.
| Highest amount reported in studies | 500 mcg per day in (they agree). higher amounts (0.3-1.0 mg daily, most studies 0.5-0.75 mg, or 1-2 mg three times weekly) - conflict with the other four. |
|---|---|
| Step-up schedules reported | Example: 300 mcg daily for the first 4 weeks, then 500 mcg daily for weeks 5-12; optional extension at 300-500 mcg. |
Route and timing
Route: Subcutaneous injection after reconstitution is the route most often described in research protocols.
Timing: Pending - to be added by SRP
Cycle length and repeat
Pending - to be added by SRP
Half-life
Approximate, for Bobby's review: Not well characterized in published research.
Side effects
Pending - to be added by SRP
Suggested bloodwork and monitoring
Draft, for Bobby's review: CBC and comprehensive metabolic panel (kidney and liver function, electrolytes) before starting and again after a few weeks; fasting glucose, HbA1c and lipid panel; lipase where GLP-1 or amylin-pathway compounds are involved.
Cautions
Pending - to be added by SRP
Reconstitution calculator
Math aid only. It converts the numbers you enter; it is not dosing advice. For research use only. Prefilled with this page's vial size, reconstitution and low-and-slow starting dose where known; change any value.
Frequently asked questions
What is AOD-9604 studied for?
In research it is studied for lipolysis and fat oxidation in rodent models, beta-3 adrenergic receptor expression and energy expenditure measurement. A modified fragment from the C-terminal end of growth hormone (residues 177-191).
How is AOD-9604 given in research?
Subcutaneous injection after reconstitution is the route most often described in research protocols. See the dosing frequency block on this page for how often.
What amount should a researcher start with?
This page lists SRP's low-and-slow starting dose in the Recommended starting dose section. Higher amounts that appear in studies are listed separately with their safety context. Start with the lower dose and contact SRP with any questions.
Related peptides
Last updated: October 19, 2026